Iovance Biotherapeutics, Inc.
IOVA · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Market Cap | – | $575 | $1,075 | $2,256 |
| - Cash | $158 | $132 | $172 | $116 |
| + Debt | $45 | $53 | $54 | $58 |
| Enterprise Value | – | $496 | $957 | $2,199 |
| Revenue | $67 | $60 | $49 | $74 |
| % Growth | 12.5% | 21.5% | -33.1% | – |
| Gross Profit | $66 | $3 | -$0 | $28 |
| % Margin | 97.9% | 5.5% | -0.8% | 38.2% |
| EBITDA | -$85 | -$102 | -$107 | -$75 |
| % Margin | -125.5% | -169.9% | -216.8% | -101.6% |
| Net Income | -$91 | -$112 | -$116 | -$79 |
| % Margin | -135.3% | -186.2% | -235.5% | -106.6% |
| EPS Diluted | -0.25 | -0.33 | -0.36 | -0.26 |
| % Growth | 24.2% | 8.3% | -38.5% | – |
| Operating Cash Flow | -$79 | -$67 | -$104 | -$73 |
| Capital Expenditures | -$11 | -$7 | -$6 | -$4 |
| Free Cash Flow | -$90 | -$75 | -$110 | -$77 |